ArticleScientific reports2025
Antipsychotics and other risk factors for mortality among people with schizophrenia during an extreme heat event: a population-based case-control study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heatwave-related variations in psychiatric consultations and admissions: a time-series analysis.Frontiers in psychiatry · 2026Article
- Climate Change, Air Pollution and the Global Obesity Syndemic: a Review of Current Evidence.Current obesity reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is associated with increased mortality during extreme heat events (EHEs), including the unprecedented 2021 Western North America EHE in British Columbia, Canada. We sought to examine the association between mortality during the 2021 EHE and multiple risk factors among people with schizophrenia, with a focus on antipsychotic medications. We identified all individuals with schizophrenia in British Columbia using an administrative chronic disease registry and linked them with antipsychotic dispensations for the 30 days prior to the EHE. We compared 137 individuals who died during the EHE with 57,394 who survived using multiple logistic regression. Analyses also included age, sex, income assistance, comorbidities, and indicators of schizophrenia severity. Dispensation of any antipsychotic was associated with increased EHE mortality [OR 2.43, 95% CI 1.52, 4.01], which was driven by haloperidol, clozapine, and zuclopenthixol. The risk was increased for dispensation of two or more antipsychotics in combination [OR 4.05, 95% CI 2.41, 6.98]. Other variables associated with EHE mortality included being on income assistance, age, sex, having a mental health-related emergency department visit, and time since disease registry entry. Being dispensed an antipsychotic prior to the EHE was associated with increased odds of mortality among people with schizophrenia. Some antipsychotics had larger effects, and risk increased with combination therapy. There were also significant non-pharmaceutical risk factors. People with schizophrenia are at-risk during EHEs due to multiple overlapping factors, including antipsychotic medications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.